| Literature DB >> 34582586 |
Lauren E Fuess1,2, Jesse N Weber3, Stijn den Haan4, Natalie C Steinel5, Kum Chuan Shim6, Daniel I Bolnick1.
Abstract
Vertebrate immunity is a complex system consisting of a mix of constitutive and inducible defences. Furthermore, host immunity is subject to selective pressure from a range of parasites and pathogens which can produce variation in these defences across populations. As populations evolve immune responses to parasites, they may adapt via a combination of (1) constitutive differences, (2) shared inducible responses, or (3) divergent inducible responses. Here, we leverage a powerful natural host-parasite model system (Gasterosteus aculeatus and Schistochephalus solidus) to tease apart the relative contributions of these three types of adaptations to among-population divergence in response to parasites. Gene expression analyses revealed limited evidence of significant divergence in constitutive expression of immune defence, and strong signatures of conserved inducible responses to the parasite. Furthermore, our results highlight a handful of immune-related genes which show divergent inducible responses which may contribute disproportionately to functional differences in infection success or failure. In addition to investigating variation in evolutionary adaptation to parasite selection, we also leverage this unique data set to improve understanding of cellular mechanisms underlying a putative resistance phenotype (fibrosis). Combined, our results provide a case study in evolutionary immunology showing that a very small number of genes may contribute to genotype differences in infection response.Entities:
Keywords: ecoimmunology; evolutionary immunology; fibrosis; host-parasite interactions
Mesh:
Year: 2021 PMID: 34582586 PMCID: PMC8796319 DOI: 10.1111/mec.16197
Source DB: PubMed Journal: Mol Ecol ISSN: 0962-1083 Impact factor: 6.622
FIGURE 1Venn diagram of overlap in significantly differentially expressed genes among all three cross type comparisons
Example list of genes differentially expressed among cross types with putative functions in immunity. A full list of differentially expressed genes for each contrast can be found in Supporting Information S1
| Transcript ID | Annotation | F2 vs. GBC | F2 vs. RBC | RBC vs. GBC | |||
|---|---|---|---|---|---|---|---|
| LFC |
| LFC |
| LFC |
| ||
| ENSGACT00000002677.1 | B‐cell receptor CD22 | 0.718 | .00504 | 1.189 | 1.81E−8 | −0.472 | .0702 |
| ENSGACT00000008607.1 | Carboxypeptidase N catalytic chain | −0.335 | .0551 | −0.654 | 4.93E−6 | 0.319 | .0848 |
| ENSGACT00000021611.1 | Complement component C8 alpha chain | 0.755 | .0863 | 1.558 | 1.16E−5 | −0.803 | .0639 |
| ENSGACT00000012995.1 | C‐type lectin domain family 4 member E | 1.207 | .0379 | 2.348 | 5.21E−7 | −1.141 | .0364 |
| ENSGACT00000024032.1 | Gelsolin | 1.784 | 3.05E−9 | −0.856 | 2.16E−4 | −0.927 | .0974 |
| ENSGACT00000005722.1 | Granulins | 0.671 | 3.01E−4 | 0.331 | .0164 | 0.340 | .0562 |
| ENSGACT00000012867.1 | H−2 class I histocompatibility antigen, L‐D alpha chain | 3.775 | 3.62E−4 | 2.026 | .0113 | 1.748 | .0798 |
| ENSGACT00000010258.1 | Histone acetyltransferase p300 | −0.477 | .0473 | −0.905 | 4.06E−6 | 0.428 | .0915 |
| ENSGACT00000001096.1 | Macrosialin | −0.506 | .0168 | −0.888 | 4.44E−7 | 0.382 | .0849 |
| ENSGACT00000002730.1 | Transforming growth factor beta activator LRRC33 | −0.616 | .00347 | −1.000 | 1.21E−8 | 0.383 | .0747 |
| ENSGACT00000024916.1 | Ubiquitin‐conjugating enzyme E2 N | 0.256 | .0927 | −0.319 | .00785 | 0.575 | 5.25E−6 |
Example list of pathways that were differentially activated among cross types and have putative functions in immunity. A full list of differentially activated pathways for each contrast can be found in Supporting Information S2
| Pathway | F2 vs. GBC | F2 vs. RBC | RBC vs. GBC | |||
|---|---|---|---|---|---|---|
|
|
|
|
|
|
| |
| B cell receptor signalling | 2.945 | .00204 | 1.889 | 3.00E−6 | 0.816 | .0398 |
| FLT3 signalling in hematopoietic progenitor cells | 2.921 | .00398 | 2.214 | 3.50E−5 | –0.535 | .0324 |
| Hepatic fibrosis signalling pathway | 5.031 | .00138 | 5.261 | 4.00E−6 | –1.677 | .0871 |
| IGF−1 signalling | 2.121 | .00407 | 1.852 | 4.70E−5 | 0 | .0912 |
| IL−2 signalling | 1.414 | .0589 | 0.816 | .00372 | –0.378 | .0871 |
| IL−6 signalling | 1.761 | .0275 | 1.387 | .00105 | –0.728 | .0776 |
| Leucocyte extravasation signalling | 3.960 | .0186 | 3.761 | 4.00E−6 | 0.200 | .0537 |
| Lymphotoxin β receptor signalling | 2.668 | .00708 | 1.225 | 9.80E−5 | –0.378 | .0537 |
| NF‐κB activation by viruses | 2.600 | .0832 | 2.03 | 3.10E−5 | –0.277 | .0479 |
| NF‐κB signalling | 3.501 | .0427 | 3.064 | 3.39E−4 | –1.091 | .0977 |
| P2Y purigenic receptor signalling pathway | 3.317 | 1.62E−4 | 2.994 | 2.24E−7 | –1.213 | .0324 |
FIGURE 2Summary of biological pathways involved in immunity that were significantly activated/inactivated as a result of infection
Comparison of infection‐associated significantly differentially expressed genes to results from a previous study (Lohman et al., 2017) using the same two source populations
| Transcript ID | Annotation | Current study | Lohman et al. | |||
|---|---|---|---|---|---|---|
| LFC |
| LFC |
| Factor | ||
| ENSGACT00000014173.1 | Annexin A2‐A | 0.811 | .00350 | 1.265 | .0730 | Infection |
| ENSGACT00000015567.1 | Chromobox protein homologue 8 | −0.367 | .0210 | −0.961 | .00699 | Infection |
| ENSGACT00000023042.1 | Dopamine beta‐hydroxylase | −0.466 | .0698 | −2.170 | .0662 | Infection |
| ENSGACT00000020041.1 | Fibronectin | 1.060 | 3.01E−12 | 0.887 | .0662 | Infection |
| ENSGACT00000004524.1 | Glycine‐‐tRNA ligase | 0.235 | .0205 | 0.592 | .0638 | Infection |
| ENSGACT00000013702.1 | Guanine nucleotide‐binding protein‐like 3‐like protein | −0.337 | .0637 | −0.393 | .0929 | Infection |
| ENSGACT00000025278.1 | Interleukin−8 | 0.462 | 5.64E−4 | 1.169 | .0582 | Interaction |
| ENSGACT00000015612.1 | Protein cornichon homologue 1 | 0.256 | .0119 | 0.455 | .0662 | Infection |
| ENSGACT00000008095.1 | SID1 transmembrane family member 2 | 0.262 | .0736 | −0.557 | .0662 | Infection |
| ENSGACT00000018426.1 | Sodium channel protein type 2 subunit alpha | −0.299 | .0938 | −1.104 | .0862 | Infection |
| ENSGACT00000011810.1 | Sorting nexin−3 | 0.326 | .00612 | 0.425 | .0662 | Infection |
| ENSGACT00000008510.1 | Tubulin alpha chain | 0.275 | .0377 | 0.978 | .0953 | Interaction |
| ENSGACT00000026489.1 | Unannotated | −0.441 | .0617 | −0.823 | .0638 | Infection |
| ENSGACT00000008169.1 | Unannotated | 1.415 | 2.05E−4 | 3.239 | .0662 | Infection |
FIGURE 3Interaction plot displaying changes in expression of the four genes that responded differentially to infection in RBC vs. GBC fish
List of genes that were significantly differentially expressed as a result of the interaction between cross type (RBC vs. GBC) and infection
| Transcript ID | Annotation | RBC vs. GBC | |
|---|---|---|---|
| LFC |
| ||
| ENSGACT00000015170.1 | CCN family member 3 | 4.866 | 1.45E−6 |
| ENSGACT00000018024.1 | Unannotated | –2.159 | .0986 |
| ENSGACT00000024555.1 | SH2 domain‐containing protein 1A | –1.202 | .0473 |
| ENSGACT00000003040.1 | U7 snRNA‐associated Sm‐like protein LSm10 | 1.157 | .0473 |
FIGURE 4Summary of biological pathways involved in immunity that were significantly activated/inactivated as a result of fibrosis
FIGURE 5Comparison of activation (z‐score) of immune‐related pathways that were significantly activated/inactivated as a result of both fibrosis and infection. Dotted line represents equivalent activation as a result of both factors; points in blue are more activated in fibrotic fish; points in red are more activated in infected fish
FIGURE 6Summary of major changes in gene expression, pathways, and upstream regulators that may affect the resistance phenotype, fibrosis. Lines above each box demonstrate up or down regulation of each component in fibrotic (blue) or infected (red) fish. Lines from each box show the predicted relationship between a given component and the fibrosis phenotype (based on existing literature). In each case arrows indicate upregulation/activation whereas blunt end lines indicate downregulation/inhibition